沉默肝脏基因可能预防罕见代谢疾病引起的脑损伤
Silencing a liver gene may prevent brain damage from rare metabolic disease
杜克大学医学院研究人员首次在小鼠模型中成功验证了针对肝脏的基因沉默疗法,治疗谷氨酸尿症I型(GA1),显著减少了脑损伤并改善了神经预后。
揭示了代谢疾病脑损伤的新治疗途径,为临床试验提供了依据。
What if the path to treating a rare condition that harms the brain goes through the liver? A new study by Duke University School of Medicine researchers is the first to show preclinical success of a liver-targeting treatment of glutaric aciduria type I (GA1).
GA1 is a rare, inherited metabolic disorder linked to the inability to properly break down the essential amino acid lysine. In childhood, this deficiency can lead to the buildup of toxic byproducts in the brain. This is believed to be the main culprit of irreversible neurological damage, in particular to areas of the brain responsible for motor function, associated with GA1.
Every newborn child in the United States is screened for GA1. Current standard of care includes a low-lysine diet and emergency interventions for acute neurological illness. But because there is no specific therapy, about a third of patients develop severe movement disorders and some complications can be fatal.
Gene silencing protects mice from brain injury
A team led by Duke pediatrics researcher Karl-Dimiter Bissig, M.D., Ph.D., used small interfering RNA (siRNA) to silence a gene involved in the breakdown of lysine. The study, published in Science Translational Medicine, is a collaboration between Duke, University of Colorado Anschutz and Alnylam Pharmaceuticals.
The researchers showed that delivering their siRNA therapy to adult mouse models kept them all alive and that treated neonatal mouse models survived better than the control group—even while on high-protein diets.
"What we have now is a translational approach," said senior author Bissig, Chen Family associate professor of pediatrics. "It gives us hope."
The researchers also inspected tissues of the treated mice and found a significant reduction in metabolic byproducts, including in the brain—which did not suffer injury in treated mice. Sorting through these tissues also led to the discovery that blood plasma harbored metabolic biomarkers that predicted neurological outcomes, pointing to a new avenue for therapeutic monitoring.
Tracing brain-damaging metabolites to the liver
This investigation builds on previous work by Bissig and collaborators, who in 2023 showed that the toxic metabolites causing brain damage were produced in the liver and crossed the blood-brain barrier. Identifying the liver as the origin of this condition was a paradigm shift for the field.
"There are these connections within the body, particularly through metabolism," said Bissig. "The liver is connected with every single organ." Using the analogy of wired versus wireless internet connections, Bissig sees the brain as hardwired to parts of the body through neurons while the liver is connected to other organs wirelessly through circulating metabolites.
Aiming for clinical trials and fewer restrictions
Bissig hopes to continue this work into clinical trials. With siRNA being a nonpermanent approach to genetic therapy and multiple siRNA drugs targeting the liver already on the market, Bissig believes the siRNA approach could provide a smooth pathway to market.
It would also be a game changer for patients who currently have to strictly monitor their diet. "You could inject patients two or three times a year, and they're protected 24/7," said Bissig. "Imagine how easy that therapy could be."
Publication details
Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aej2067
Journal information: Science Translational Medicine
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Silencing a liver gene may prevent brain damage from rare metabolic disease (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-silencing-liver-gene-brain-rare.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com